CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
RO5185426drug
Likely dose
RO5185426 960 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01253564
NCT01253564Phase 2Completed
CompareCT.gov

An Open-label, Pilot Study of RO5185426 in Previously Treated Metastatic Melanoma Patients With Brain Metastases

Hoffmann-La Roche·interventional·Posted Dec 3, 2010·Updated Jul 31, 2017

In Brief

A Phase 2 clinical trial evaluating RO5185426 for Malignant Melanoma. Completed, enrolled 24 participants across 2 sites.

Detailed Summary

This open-label study will assess the safety and efficacy of RO5185426 in previously treated metastatic melanoma patients with brain metastases. Patients will receive RO5185426 at a dose of 960 mg twice daily orally until disease progression or unacceptable toxicity occurs.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Melanoma
CountriesSwitzerland
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 3, 2010
Enrollment StartNov 22, 2010
Primary CompletionMar 14, 2012
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 15.6 years ago

Interventions

RO5185426drug

960 mg b.i.d. orally